Literature DB >> 475949

A dose-response study of the anticoagulant and lipolytic activities of heparin in normal subjects.

A C Asmal, W P Leary, F Thandroyen, J Botha, S Wattrus.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 475949      PMCID： PMC1429583          DOI： 10.1111/j.1365-2125.1979.tb01000.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  7 in total

1.  Editorial: Lwo=dose heparin prophylaxis for postoperative venous thromboembolism.

Authors:  S Sherry
Journal:  N Engl J Med       Date:  1975-08-07       Impact factor: 91.245

2.  Reversible abnormalities in postheparin lipolytic activity during the late phase of release in diabetes mellitus (postheparin lipolytic activity in diabetes).

Authors:  J D Brunzell; D Porte; E L Bierman
Journal:  Metabolism       Date:  1975-10       Impact factor: 8.694

3.  DETERMINATION OF HEPARIN-INDUCED LIPOPROTEIN LIPASE ACTIVITY IN HUMAN PLASMA.

Authors:  J BOBERG; L A CARLSON
Journal:  Clin Chim Acta       Date:  1964-11       Impact factor: 3.786

4.  The production of lipolytic activity in the circulation of the hind limb in response to heparin.

Authors:  D S ROBINSON; P M HARRIS
Journal:  Q J Exp Physiol Cogn Med Sci       Date:  1959-01

5.  Lipoprotein-lipase responses to heparin.

Authors:  C M Morris; J Kirumba; R W Furneaux; J M Ham
Journal:  Br J Surg       Date:  1971-02       Impact factor: 6.939

6.  Differences in heparin-released lipolytic activity in the superficial and deep veins of the human forearm.

Authors:  D J Heaf; L Kaijser; B Eklund; L A Carlson
Journal:  Eur J Clin Invest       Date:  1977-06       Impact factor: 4.686

Review 7.  Heparin, heparin-activated enzymes and platelets.

Authors:  J M Ham; J C Lawrence
Journal:  Haemostasis       Date:  1977
  7 in total
  15 in total

1.  Characterization of a highly effective preparation for suppression of myocardial glucose utilization.

Authors:  Sophia R Larson; Justin A Pieper; Edward A Hulten; Edward P Ficaro; James R Corbett; Venkatesh L Murthy; Richard L Weinberg
Journal:  J Nucl Cardiol       Date:  2019-06-24       Impact factor: 5.952

2.  Patient preparation for cardiac fluorine-18 fluorodeoxyglucose positron emission tomography imaging of inflammation.

Authors:  Michael T Osborne; Edward A Hulten; Venkatesh L Murthy; Hicham Skali; Viviany R Taqueti; Sharmila Dorbala; Marcelo F DiCarli; Ron Blankstein
Journal:  J Nucl Cardiol       Date:  2016-06-08       Impact factor: 5.952

Review 3.  Recommendations for 18F-fluorodeoxyglucose positron emission tomography imaging for diagnosis of cardiac sarcoidosis-2018 update: Japanese Society of Nuclear Cardiology recommendations.

Authors:  Shinichiro Kumita; Keiichiro Yoshinaga; Masao Miyagawa; Mitsuru Momose; Keisuke Kiso; Tokuo Kasai; Masanao Naya
Journal:  J Nucl Cardiol       Date:  2019-08       Impact factor: 5.952

4.  Joint SNMMI-ASNC expert consensus document on the role of 18F-FDG PET/CT in cardiac sarcoid detection and therapy monitoring.

Authors:  Panithaya Chareonthaitawee; Rob S Beanlands; Wengen Chen; Sharmila Dorbala; Edward J Miller; Venkatesh L Murthy; David H Birnie; Edward S Chen; Leslie T Cooper; Roderick H Tung; Eric S White; Salvador Borges-Neto; Marcelo F Di Carli; Robert J Gropler; Terrence D Ruddy; Thomas H Schindler; Ron Blankstein
Journal:  J Nucl Cardiol       Date:  2017-10       Impact factor: 5.952

5.  Optimizing myocardial metabolism for fluorine-18 fluorodeoxyglucose positron emission tomography imaging of cardiac inflammation.

Authors:  Efstathia Andrikopoulou; Pradeep Bhambhvani
Journal:  J Nucl Cardiol       Date:  2017-04-21       Impact factor: 5.952

6.  ASNC imaging guidelines/SNMMI procedure standard for positron emission tomography (PET) nuclear cardiology procedures.

Authors:  Vasken Dilsizian; Stephen L Bacharach; Rob S Beanlands; Steven R Bergmann; Dominique Delbeke; Sharmila Dorbala; Robert J Gropler; Juhani Knuuti; Heinrich R Schelbert; Mark I Travin
Journal:  J Nucl Cardiol       Date:  2016-07-08       Impact factor: 5.952

7.  Challenges of cardiac inflammation imaging with F-18 FDG positron emission tomography.

Authors:  Pradeep Bhambhvani
Journal:  J Nucl Cardiol       Date:  2016-05-04       Impact factor: 5.952

Review 8.  Disease-induced changes in the plasma binding of basic drugs.

Authors:  K M Piafsky
Journal:  Clin Pharmacokinet       Date:  1980 May-Jun       Impact factor: 6.447

9.  Elevated (18)F-fluorodeoxyglucose uptake in the interventricular septum is associated with atrioventricular block in patients with suspected cardiac involvement sarcoidosis.

Authors:  Osamu Manabe; Hiroshi Ohira; Keiichiro Yoshinaga; Takahiro Sato; Alisa Klaipetch; Noriko Oyama-Manabe; Yoichi M Ito; Ichizo Tsujino; Masaharu Nishimura; Nagara Tamaki
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-05-29       Impact factor: 9.236

Review 10.  The role of F(18)-fluorodeoxyglucose positron emission tomography in guiding diagnosis and management in patients with known or suspected cardiac sarcoidosis.

Authors:  B A Mc Ardle; E Leung; H Ohira; M S Cocker; R A deKemp; J DaSilva; D Birnie; R S Beanlands; P B Nery
Journal:  J Nucl Cardiol       Date:  2013-01-04       Impact factor: 5.952
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.